Will Disclosure Quiet the Industry’s Critics? Peter Lurie, MD, MPH Deputy Director Health Research Group at Public Citizen Presented before The National.

Slides:



Advertisements
Similar presentations
Competing interests Jaideep A Gogtay MD Conflict of Interest Employee of Cipla Ltd.
Advertisements

Marketing to Doctors – Payments for Loyalty Julie Brill Assistant Attorney General Vermont Attorney General ’ s Office Montpelier,
1 Physician-Industry Transparency: The U.S. Physician Payment Sunshine Act.
Managing Conflict of Interest The Challenge of Pharmaceutical Company Marketing to Medical Professionalism David J. Rothman, Ph.D. Bernard Schoenberg Professor.
William H. Maisel, MD, MPH Director, Medical Device Safety Institute Beth Israel Deaconess Medical Center Statement to the FDA Risk Communication Advisory.
How data can improve health care What we don’t know can hurt us Gov 2.0 September 10, 2009 Elliott Fisher, MD, MPH Director, Population Health and Policy.
Conflict of Interest. Definition  “A conflict of interest is a situation in which financial or other personal considerations have the potential to compromise.
Third-Party Reprocessing: Industry Update Daniel J. Vukelich, President Association of Medical Device Reprocessors (AMDR)
Conflicts of Interest James G. Anderson, Ph.D. Department of Sociology & Anthropology.
Security of Computerized Medical Information: Threats from Authorized Users James G. Anderson, Ph.D. Purdue University.
Conflict of Interest in Medical Research, Education, and Practice Presentation for Secretary’s Advisory Committee on Human Research Protections July 22,
Promoting Objectivity in Research by Managing, Reducing, or Eliminating Conflicts of Interest UT HOP UT HOP The University of Texas at Austin.
Help! I’m On James A Colbert MD Newton-Wellesley Hospital Brigham & Women’s Hospital Bradley H Crotty MD MPH FACP Beth Israel Deaconess Medical Center.
The Prescription Project: Ending Conflicts of Interest; Promoting Evidence-Based Prescribing Marcia Hams, Director of Prescription Policy Initiatives The.
“opinion or feeling that strongly favours one side in an argument or one item in a group or series”
Conflict of Interest Curriculum Eric Jackson, PharmD University of Connecticut School of Medicine Department of Family Medicine.
Teaching Professionalism to Residents: The Management of Conflict of Interest in Medicine NORMAN B. KAHN, JR. MD COUNCIL OF MEDICAL SPECIALTY SOCIETIES.
Professionalism and the CRNA
Introductory training Medical Technology Industry Code of Practice.
Open Payments Act AKA the ‘Sunshine Act’ Open Payments Act AKA the ‘Sunshine Act’ Public Postings of Physician Ownership, Investments, & Transfers of Value.
Implementation of Disclosure Legislation in Massachusetts National Disclosure Summit March 6, 2009 Allan Coukell, Director of Policy.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
North Shore – LIJ Health System PREP Workshop #4: How to Report and Manage External Interests (COIs) Electronically.
The Truth About the Drug Companies Marcia Angell, M.D.
State Ethics & Lobbying Laws for Pharmaceutical and Medical Device Companies John T. Bentivoglio (202) Steve Benz
The Needs of Pediatric Practices for Policy and Procedures to Facilitate Youth with Special Health Care Needs (YSHCN) Transition to Adulthood. Patience.
CONFIDENTIALITY The promise of NOT to share personal information inappropriately. Grounded in an individual’s right of privacy.  “DO NO HARM” Slide 2.
© 2013 Federation of State Medical Boards. Handling Medical Complaints Fairly and Transparently J. Daniel Gifford, MD, Chair-Elect Federation of State.
CONFLICTS OF INTEREST PRESENTED BY THE UMMC OFFICE OF INTEGRITY AND COMPLIANCE.
G. Scott Gazelle, MD, MPH, PhD Director, Partners Radiology Partners Radiology Research Retreat February 26, 2010.
Big data and cognitive computing at point of care. A big challenge: How we should manage it at the Primary Care? Josep M Picas.
Security of the Distributed Electronic Patient Record: A Case-Based Approach James G. Anderson, Ph.D. Purdue University.
Transparency in Grants and Gifts Pfizer Approach Cathryn Clary, MD VP, US External Medical Affairs.
Understanding the Forces Driving Disclosure Preconference Session First Annual Summit on Sales & Marketing Disclosure for Drug, Device and Biotech Companies.
+ Conflict of Interest in Physician-Industry Relationships.
PHS COI Policy Update Grace Park, COIOC Administrator Office of Research June 2012.
Vendor Relations Policy. Why Is There A Policy? The Patient Protection and Affordable Care Act was signed into law March 23, The new law contains.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
Measuring and Rewarding Physician Performance: A National Movement David S. P. Hopkins, Ph.D. Pacific Business Group on Health Provider Reimbursement Web.
A presentation of The Association of the Pharmaceutical Industry in Norway (LMI)
+ Role of Industry in Clinical Care, Research, and Education.
2008 Synergy Workshop Institute of Medicine Washington, DC.
An Educational Session on HSC OP 10.27, Health Care Vendor Interactions April 20, 2009.
1 Continuing Medical Education and Industry Sponsorship The Pharma, Biotech and Device Colloquium Princeton, NJ June 7, 2005 Julie K. Taitsman, M.D., J.D.
Copyright © Harvard Medical School. All Rights Reserved. Outside Activity Report: What Do I Need to Report?
The Physician - Pharma Relationship.  Is very old and very close  But are the goals of pharmaceutical companies and medicine the same?
Systematic Reviews and American College of Physicians Clinical Practice Guidelines Amir Qaseem, MD, PhD, MHA, FACP Director, Clinical Policy American College.
National Medical Device Audioconference: How the Recent Landmark $311 Million Device Settlements Will Change Industry Practices Insights Into Federal Investigations.
Bringing Health Information to Life DAVID BLUMENTHAL, MD, MPP National Coordinator of Health Information Technology US Department of Health & Human Services.
Health Information Technology Summit John Tooker, MD, MBA, FACP Executive Vice President/CEO American College of Physicians Washington, DC October 21,
Second Annual Medical Research Summit March 25, 2002 Washington, D.C.
How Big Pharma Should Change Peter Lurie, MD, MPH Health Research Group at Public Citizen Presented at Eighth Annual Pharmaceutical Regulatory and Compliance.
Physicians & Social Media: There’s an App for That Merry-Jennifer Markham, MD, FACP University of Florida College of
B uilding Blocks for Effective Primary Care for the Underserved: A Bold New Curriculum? Walt Mills, MD UCSF Natividad FMR Monterey, California Jeremy Fish,
PATIENT SAFETY ORGANIZATION Michigan Surgical Quality Collaborative
Pharmaceutical industry interactions in family medicine residencies have decreased since 2008 Steven R. Brown, MD, David V. Evans, MD, Adriane Fugh-Berman,
AFFORDABLE CARE ACT: OVERVIEW, STUDY OF THE GENERAL EFFECTS ON RADIOLOGY, HOW FAR HAVE WE COME AND THE FUTURE Bhavya Rehani, MD, Lindsay P. Busby, MD,
Hospitals and Health Systems
Ethical and legal issues related to blogging and social media
Ann Intern Med. 2014;160(11): doi: /M Figure Legend:
UCR PRO Reviewer Placemat
Sneak Preview: The Revised PHS FCOI Regulations
FDA-CDRH in the Next Decade A Vision for Change
The Physician Payments Sunshine Act
Continuing Medical Education Commercial Disclosure Requirement
Bert Weinstein, VP, Corporate Compliance Purdue Pharma L.P.
An Introduction to the Sunshine Act
Physician Payments Sunshine Act of 2009 – S. 301
September 16, 2011  12:00-1:00 pm Eastern Presenters:
Updates to the PhRMA Code on Interactions with Healthcare Professionals National Pharma Audioconference August 5, 2008.
Presentation transcript:

Will Disclosure Quiet the Industry’s Critics? Peter Lurie, MD, MPH Deputy Director Health Research Group at Public Citizen Presented before The National Disclosure Summit Washington, DC March 5, 2009

Why a Doctor Gifts Registry? Transparency/accountability to patients

Statement by American College of Physicians “What would my patients think about this arrangement? What would the public think? How would I feel if the relationship was disclosed through the media?” Source: Ann Intern Med 2002;136:

Why a Doctor Gifts Registry? Transparency/accountability to patients Restore trust in medical profession Facilitates kickback investigations Transparency/accountability to providers Transparency/accountability to payors Promotes research (esp. if names provided) Facilitates journalistic investigations

Uses by Journalists Investigative pieces by local journalists Comparisons by specialty Links to “thought leaders” Links to state disciplinary actions

Public Disclosure of Pharmaceutical Company Gifts to Physicians, VermontMinnesota Threshold$25$100 Trade secret exemption? YesNo Electronic?YesNo Reporting period2 years3 years Median physician gift >$100 (maximum) $250 ($20,000)$1000 ($922,239) Total physician gifts$3.2 million$22.4 million Sources: JAMA 2007;297: ; JAMA 2008;300:

Purpose of Payments >$100 to Physicians in Vermont,

Public Disclosure of Pharmaceutical Company Gifts to Physicians, High rates of underreporting –Companies report $millions one year, nothing the next Responses non-standardized –Aggregation by physician and by gift Exemptions –Samples –Research studies Limited accessibility –Lack of online submissions or reports –Need to file lawsuit in Vermont Lack of national standardization

Problems with the Physician Payment Sunshine Act, 2009 Exclusions –Samples –Research on unapproved products –Gifts totaling <$100 per year –Gifts to other professionals No payments to organizations –MECCs and PBMs –Patient groups –Hospitals and medical schools –Professional organizations No judicial review Low penalties –Intentional non-reporting: cap of $1 million/year

Framework for Addressing Conflict of Interest Potential Conflict Legal Restrictions Policy Restrictions Disclosure

Research Payments to Physicians Research Payments Legal Restrictions Not Desirable Not Feasible Policy Restrictions Pool of Research Funds Disclosure Some journals Some presentations

Non-research Payments to Physicians Non-research Payments Legal Restrictions Limited Political Feasibility Policy Restrictions Institutional Restrictions Boston University University of Michigan University of Pennsylvania Yale University Stanford University Boston Medical Center Geisinger Health System Affinity Health System Kaiser Permanente HealthPartners Disclosure State or Federal Databases

Pharmaceutical Company Promotional Expenditures, U.S., 2004 Total expenditures –Promotion: $57.5 billion –Research: $31.5 billion As % of retail sales –Promotion: 24.4% –Research: 13.4% $61,000 on promotion per physician Source: PLOS Medicine 2008;5:e1

Q: Will Disclosure Quiet the Industry’s Critics?

Q: Will Disclosure Quiet the Industry’s Critics? A: No